Clinical Trial Search

Primary: Distribution Volume Ratio (DVR) — 1.30; 1.39; 1.26; 1.34 Distribution Volume Ratio (DVR) — p=<0.02

Primary: Tau Protein Uptake.. — 1.1871; 1.1652; 1.5910 SUVr

Primary: Flortaucipir Visual Read as CTE Biomarker — 23; 11; 5; 0 Participants — p=0.2959

Primary: Change in Executive Functioning as Assessed by the Trail Making Test — -9.2; 24.7 change in seconds — p=.323

Primary: The Feasibility of Inpatient Bedside Neurocognitive Testing of Pediatric Patients With Minor Traumatic Brain Injury. — 120 participants

Primary: Mean Difference in Change in Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) Score at Baseline and 6 Weeks. — -0.9; -5.78; 3.52; -7.26 Units on a scale

Primary: Trail Making Test Part B — 52.1; 45.3; 52.9; 50.8 T-score

Primary: Cognitive Composite Score for Group of Subjects With TBI and Healthy Controls Matched by Age, Education, and Treatment Group. — 42.750; 50.500; 49.500; 55.000 T-score…

Primary: Brief Symptom Inventory-18 (BSI-18) Global Severity Index T-Score — 64.21; 65.26; 66.8; 61.35 units on a scale — p=.04

Primary: Liver Function Testing (Aspartate Transaminase [AST]/Alanine Transaminase [ALT] Ratios) to Screen for Adverse Events. — 1.57; 1.24 AST/ALT ratio

Primary: Change in Insomnia Severity — 8.833; 7.810; 9.625; 8.364 score on a scale

Primary: Longitudinal DTI Changes — 0.000809; 0.000760; 0.000763; 0.000843 voxels

Primary: Memory Test Accuracy on Trained Stimuli — 53.9; 37.6; 48.9; 37.3 Percent correct

Primary: Performance on Multiple Sleep Latency Test (MSLT) — 6.67; 7.32; 6.73; 7.88 minutes

Primary: Brief Assessment of Cognition in Affective Disorders (BAC-A) — 0.61; 0.80 units on a scale

Primary: Determine Average Number of Hits Between Groups — 896.43; 795.40; 144.67; 145.85 number of hits

Primary: CAPS (Cluster D Symptoms) - PRIMARY BEHAVIORAL OUTCOME MEASURE — 13.88; 12.89; 11.23; 10.89 Score

Primary: Examiner Score — 0.617; 0.907; 0.865; 1.155 score on a scale

Primary: Mismatch Negativity (MMN) Amplitudes in Microvolts — -0.59; -1.19; -0.41; -0.65 microvolts

Primary: Change in Performance on Neurocognitive Measure of Attention and Executive Function Post GOALS Intervention vs EDU Control Training — -0.03; -0.39 z score — p=<0.01

Primary: Glasgow Outcome Scale Extended (GOSE) — 7; 5 Glasgow Outcome Scale Extended (GOSE)

Primary: Composite Score of Attention and Executive Functioning From a Neurocognitive Test Battery — 0.18; -0.06 units on a scale

Primary: Percent Change in Trail Making Test Part B Time to Completion — -25.6 percent change in time

Primary: Time (in Days) That a Patient Reports Symptoms From Their Concussion. — 7.3; 4.5 Days Symptomatic — p=.42

Primary: Change From Baseline in RPQ Score at Post-treatment Sessions — -4.6; -3.4 units on a scale

Primary: Receptor Binding (Vt) — 2.53; 2.21; 3.21; 3.22 mL/cm^3

Primary: Iowa Gambling Test — -4.2; 1.7; 3.5; 5.3 Total Raw on a scale from -100 to 100 — p=>.05

Primary: Change in Abnormal Magnetoencephalography (MEG) Slow-Waves (1-4 Hz) Activity — 1.8; 0.2; 0 units on a scale — p=0.01

Primary: Flortaucipir Imaging (Quantitative) Between Cognitive Groups — 1.0048; 0.971; 0.9731; 0.9357 standardized uptake value ratio (SUVr)

Primary: Number of Headache Days Per Week — 4.2; 4.6; 3.1; 4.3 days/week — p=<0.000